

## MariMed CIO Žiburkus to Talk at Institutional Capital & Cannabis Conference

• 3<sup>rd</sup> Annual Institutional Capital & Cannabis Conference – May 9-10 – JW Marriott Hotel, 900 West Olympic Boulevard, Los Angeles 90015

NORWOOD, MA, May 07, 2019 (GLOBE NEWSWIRE) -- <u>MariMed Inc.</u> (OTCQB: MRMD) one of the largest multi-state cannabis and hemp operators in the US, announced today that its Chief Information Officer, Dr. Jokūbas Žiburkus, will be presenting at the 3<sup>rd</sup> Institutional Capital & Cannabis Conference held in Los Angeles, CA, May 9-10, 2019.

On Thursday, May 9<sup>th</sup> Dr. Žiburkus will be one of the three experts in a panel discussion at 11:40 AM. The subject of the panel discussion will be *Impact Investing: Medical Efficacy and Societal Impact of Legal Cannabis*.

MariMed CEO Bob Fireman noted, "Dr. Žiburkus has long been an innovator and thought leader in research and education on beneficial effects of cannabis compounds for a variety of health conditions. As an entrepreneur, he led the development of the hemp-derived health and wellness line of products Florance™, now a premium MariMed Hemp Inc. brand line available in the U.S., Europe, and spreading to other parts of the globe. As the newest member of MariMed's senior management team, we are pleased that he continues to be at the forefront of innovations for MariMed and the broader industry."

## About MariMed Inc.

MariMed, Inc. is dedicated to improving health and wellness with the highest quality hemp and cannabis products. The company offers a full range of cannabis products, operates state of the art cannabis dispensaries in six states, and has recently announced the formation of a separate division, MariMed Hemp, focused on the development of industrial hemp-derived CBD products. In late 2018 the Company announced a \$30MM investment in Kentucky-based GenCanna, a recognized genetic innovator in industrial hemp. Across its branded products, MariMed is in the forefront of precision dosed branded products for the treatment of specific medical symptoms. MariMed currently distributes its branded products in select states and is expanding licensing and distribution to numerous additional markets encompassing thousands of dispensaries.

For additional information, visit www.MariMedAdvisors.com.

Search MariMed and post on social media with the hash tag #MedicatedByMariMed:

Twitter: @MariMedInc Facebook: @MariMedInc Instagram: MariMedInc YouTube:

MariMedInc

## **Forward Looking Statements:**

This release contains certain forward-looking statements and information relating to MariMed Inc. that is based on the beliefs of MariMed Inc.'s management, as well as assumptions made by and information currently available to the Company. Such statements reflect the current views of the Company with respect to future events including estimates and projections about its business based on certain assumptions of its management, including those described in this Release. These statements are not guarantees of future performance and involve risk and uncertainties that are difficult to predict, including, among other factors, changes in demand for the Company's services and products, changes in the law and its enforcement and changes in the economic environment. Additional risk factors are included in the Company's public filings with the SEC. Should one or more of these underlying assumptions prove incorrect, actual results may vary materially from those described herein as "hoped," "anticipated," "believed," "planned, "estimated," "preparing," "potential," "expected," "looks" or words of a similar nature. The Company does not intend to update these forward-looking statements. None of the content of any of the websites referred to herein (even if a link is provided for your convenience) is incorporated into this release and the Company assumes no responsibility for any of such content.

**Media:** Julie Shepherd, Accentuate PR Julie@accentuatepr.com 847-275-3643

Investors: Jon Levine, CFO, MariMed info@MariMedAdvisors.com 781-559-8713



Source: MariMed Inc.